Traceability of Cellular Cycle Anomalies Targeting Oncology and Neurodegeneration

Abstract

The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. It is a diagnostic test and a prognostic test for various cancers (breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, glioblastoma, sarcoma, leukemia, etc.) and therapeutics solutions for specific neurodegenerative diseases. More particularly, the invention concerns the use of the LIV21 protein, LIV21 gene and of derivatives thereof as diagnostic and prognostic markers for cancers. The invention therefore concerns the detection of the LIV21 protein with a kit comprising LIV21-specific antibodies.

1 . A method for the detection of cancer cells in a biological sample from a patient, comprising the detection of the product of expression of the LIV21 gene in the nucleus and/or cytoplasm of the cells in a sample of cells in the biological sample from said patient, localization of said product of expression of LIV21 gene in the cytoplasm being indicative of the presence of cancer cells and localization of said product of expression of the LIV21 gene in the nucleus being indicative of the presence of noncancer cells. 
     
     
         2 . The method as claimed in  claim 1 , in which localization of said product of expression of the LIV21 gene in the cytoplasm is indicative of the presence of invasive and/or metastatic cancer cells. 
     
     
         3 . The method as claimed in  claim 1 , also comprising the detection of the product of expression of at least three genes selected from the group consisting of the protein kinase C epsilon (PKCε) gene, the E2F1 gene, the E2F4 gene and HDAC1. 
     
     
         4 . The method as claimed in  claim 3 , in which at least one of the ratios LIV21/PKCε, LIV21/E2F4 and LIV21/E2F1 is determined. 
     
     
         5 . The method as claimed in  claim 1 , in which the expression product of the genes is detected at the mRNA level or a isolated polynucleotide (SEQ ID No: 119-148) related to LIV21 gene. 
     
     
         6 . The method as claimed in  claim 1 , also comprising the detection of the product of expression of at least five genes or antibodies specific for a protein selected from the group consisting of RBP2, E2F4, E2F2, E2F1, SUMO1, SUMO3, HDAC1, cycE/cdk2, cdk1, CREB1, p300, Rb, PML, p107 and p130 of the pocket protein family. 
     
     
         7 . The method as claimed in  claim 1 , also comprising the detection of the product of expression of at least five genes selected from NFkB, cdc2A, mdm2, p21, p53, p65, Ki67, erk, CD53 and CAF1. 
     
     
         8 - 11 . (canceled) 
     
     
         12 . The method as claimed in  claim 3 , in which significant increase in PKCε is indicative of the presence of cancer cells. 
     
     
         13 . (canceled) 
     
     
         14 . The method as claimed in  claim 3 , for the detection of metastasized cancer, therapeutic monitoring and/or recurrences following treatment. 
     
     
         15 - 24 . (canceled) 
     
     
         25 . The method as claimed in  claim 1 , in which the cancer is selected from breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostrate cancer, colon cancer, liver cancer, a sarcoma, a leukemia, and glioblastoma. 
     
     
         26 . The use of an oligonucleotide specific probe of LIV21 mRNA or isolated polynucleotide (SEQ ID Nos. 119-198) as claimed in  claim 5  or specific primers of LIV21 mRNA for the diagnosis of cancer related to the LIV21 gene. 
     
     
         27 - 33 . (canceled)